DE69935335D1 - Pyrazole als modulatoren des östrogenrezeptors - Google Patents
Pyrazole als modulatoren des östrogenrezeptorsInfo
- Publication number
- DE69935335D1 DE69935335D1 DE69935335T DE69935335T DE69935335D1 DE 69935335 D1 DE69935335 D1 DE 69935335D1 DE 69935335 T DE69935335 T DE 69935335T DE 69935335 T DE69935335 T DE 69935335T DE 69935335 D1 DE69935335 D1 DE 69935335D1
- Authority
- DE
- Germany
- Prior art keywords
- estrogen receptor
- pyrazole
- modulators
- compounds
- modulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000015694 estrogen receptors Human genes 0.000 title abstract 4
- 108010038795 estrogen receptors Proteins 0.000 title abstract 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Developing Agents For Electrophotography (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9577298P | 1998-08-07 | 1998-08-07 | |
US95772P | 1998-08-07 | ||
PCT/US1999/017799 WO2000007996A2 (en) | 1998-08-07 | 1999-08-06 | Pyrazoles as estrogen receptor modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69935335D1 true DE69935335D1 (de) | 2007-04-12 |
DE69935335T2 DE69935335T2 (de) | 2007-11-22 |
Family
ID=22253525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69935335T Expired - Lifetime DE69935335T2 (de) | 1998-08-07 | 1999-08-06 | Pyrazole als modulatoren des östrogenrezeptors |
Country Status (8)
Country | Link |
---|---|
US (3) | US6291505B1 (de) |
EP (1) | EP1102753B1 (de) |
JP (1) | JP2002522422A (de) |
AT (1) | ATE355279T1 (de) |
AU (1) | AU5467799A (de) |
DE (1) | DE69935335T2 (de) |
ES (1) | ES2281186T3 (de) |
WO (1) | WO2000007996A2 (de) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6878729B2 (en) * | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
BR0211067A (pt) * | 2001-07-09 | 2006-10-31 | Zonagen Inc | métodos e materiais para o tratamento de deficiência de testosterona em homens |
US7737185B2 (en) * | 2001-07-09 | 2010-06-15 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
US20040010027A1 (en) * | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
WO2003055860A1 (en) * | 2001-12-21 | 2003-07-10 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
WO2003062192A1 (en) * | 2002-01-17 | 2003-07-31 | Smithkline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
WO2003097609A1 (en) | 2002-05-15 | 2003-11-27 | Janssen Pharmaceutica N.V. | N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors |
EP1398029A1 (de) * | 2002-09-10 | 2004-03-17 | LION Bioscience AG | 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden |
GB0228417D0 (en) * | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
US20060172019A1 (en) * | 2003-03-07 | 2006-08-03 | Ralston Stuart H | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
US20050113423A1 (en) * | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
US7205329B2 (en) * | 2003-05-30 | 2007-04-17 | Microbia, Inc. | Modulators of CRTH2 activity |
US20070161698A1 (en) * | 2003-05-30 | 2007-07-12 | Microbia, Inc. | Modulators of CRTH2 Activity |
US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
EP1643961A4 (de) * | 2003-07-01 | 2007-09-12 | Microbia Inc | Cox-2- und faah-hemmer |
US20070293542A1 (en) * | 2003-10-16 | 2007-12-20 | Cali Brian M | Selective Cox-2 Inhibitors |
US8088758B2 (en) | 2003-11-12 | 2012-01-03 | Abbott Products Gmbh | 17β-hydroxysteroid dehydrogenase type I inhibitors |
AU2004303602C1 (en) | 2003-12-23 | 2009-05-28 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
US20050234030A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
US20050234244A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Synthesis of COX-2 and FAAH inhibitors |
WO2006019916A1 (en) * | 2004-07-14 | 2006-02-23 | Repros Therapeutics Inc. | Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol |
WO2006033943A2 (en) * | 2004-09-17 | 2006-03-30 | Exelixis, Inc | Pyrazole kinase modulators and methods of use |
US20090082322A1 (en) * | 2004-10-09 | 2009-03-26 | The Regents Of The University Of Michigan | Gender Differences in Experimental Aortic Aneurysm Formation |
PE20060949A1 (es) * | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
KR20070100811A (ko) * | 2005-02-04 | 2007-10-11 | 레프로스 쎄라피우틱스 아이엔씨. | 남성불임의 치료를 위한 트랜스―클로미펜을 이용한 물질과치료방법 |
JP5785680B2 (ja) * | 2005-03-22 | 2015-09-30 | リプロス セラピューティクス インコーポレイテッド | トランス−クロミフェン用の投与レジメン |
TW200720254A (en) * | 2005-04-07 | 2007-06-01 | Nippon Kayaku Kk | Use of 3,5-diphenyl pyrazole derivatives as anti-tumor agent |
WO2006116401A1 (en) * | 2005-04-28 | 2006-11-02 | Bristol-Myers Squibb Company | C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators |
US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
EP1902032A1 (de) | 2005-06-22 | 2008-03-26 | Astex Therapeutics Limited | Pharmazeutische verbindungen |
JP5345842B2 (ja) * | 2005-06-23 | 2013-11-20 | アステックス・セラピューティクス・リミテッド | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
WO2008011453A2 (en) * | 2006-07-20 | 2008-01-24 | Amgen Inc. | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 |
US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
US20080096950A1 (en) * | 2006-10-19 | 2008-04-24 | Karl Richard Gibson | Compounds Useful In Therapy |
US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
EP2826475B1 (de) | 2007-10-16 | 2019-03-20 | Repros Therapeutics Inc. | Trans-Clomiphen zur Behandlung von Diabetes bei hypogonodalen Männer |
CA2728095A1 (en) * | 2008-07-17 | 2010-01-21 | Asahi Kasei Pharma Corporation | Pyrazole-containing tricyclic compounds as antagonists of an ep1 receptor |
JP5689069B2 (ja) | 2008-11-20 | 2015-03-25 | ジェネンテック, インコーポレイテッド | ピラゾロピリジンpi3k阻害剤化合物及び使用方法 |
AR078538A1 (es) | 2009-10-07 | 2011-11-16 | Karobio Ab | Pirroles e imidazoles sustituidos como ligandos del receptor de estrogenos |
MX2012012410A (es) | 2010-04-28 | 2012-12-17 | Toray Industries | Agente terapeutico y agente preventivo para enfermedad de alzheimer. |
GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
US9475816B2 (en) | 2012-09-07 | 2016-10-25 | Takeda Pharmaceutical Company Limited | Substituted-1,4-dihydropyrazolo[4,3-b]indoles |
AU2013338311A1 (en) | 2012-11-02 | 2015-05-14 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
EP3013846B1 (de) | 2013-06-25 | 2017-08-09 | Forendo Pharma Ltd | Therapeutisch aktive 17-stickstoff-substituierte estratrienthiazolderivate als inhibitoren der 17-beta-hydroxysteroid-dehydrogenase |
CN105518017B (zh) | 2013-06-25 | 2020-07-14 | 佛恩多制药有限公司 | 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物 |
TW201512215A (zh) | 2013-06-25 | 2015-04-01 | Forendo Pharma Ltd | 治療活性雌三烯噻唑衍生物 |
CN104016921A (zh) * | 2014-03-24 | 2014-09-03 | 南开大学 | 具有抗肝癌活性的1-取代苯基-4-多取代苯基-5-甲硫基-1h吡唑类化合物 |
CN107207562B (zh) | 2014-12-23 | 2020-03-06 | 佛恩多制药有限公司 | 17β-HSD1抑制剂的前药 |
US10413557B2 (en) | 2014-12-23 | 2019-09-17 | Forendo Pharma Ltd. | Prodrugs of 17.BETA.-HSD1-inhibitors |
WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
CN105523955B (zh) * | 2015-12-14 | 2018-08-17 | 北京嘉林药业股份有限公司 | 化合物及其在制备药物中的用途 |
GB201706806D0 (en) | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
EP3759104A1 (de) * | 2018-03-02 | 2021-01-06 | Université de Lausanne | Pyrazolderivate als inhibitoren des wnt-signalweges |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4146721A (en) * | 1969-09-12 | 1979-03-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyrazol-4-acetic acid compounds |
FR2104932A1 (en) | 1970-09-08 | 1972-04-28 | Ferlux | O-hydroxyphenyl pyrazoles - hypocholesterolemics anti inflammatories analgesics etc |
ZA744908B (en) | 1973-09-17 | 1975-08-27 | American Cyanamid Co | Catalytic dehydrogenation process for the preparation of 3,5-disubstituted pyrazoles |
US4112108A (en) | 1976-12-06 | 1978-09-05 | Sandoz, Inc. | Isoxazolyl benzamides |
US4229204A (en) | 1978-12-04 | 1980-10-21 | Monsanto Company | Trifluoromethylphenyl isoxazolyl benzoates |
CA1128526A (en) | 1979-10-05 | 1982-07-27 | Cdc Life Sciences Inc. | 3,4-diarylisoxazol-5-acetic acids |
DE3119727A1 (de) | 1981-05-18 | 1982-12-02 | Sterling Drug Inc., 10019 New York, N.Y. | "4-(arylaliphatische)-isoxazole, welche als antivirale mittel nuetzlich sind, und deren herstellung" |
CA2036192A1 (en) | 1990-02-13 | 1991-08-14 | Nicholas Meanwell | Heterocyclic carboxylic acids and esters |
DE4126543A1 (de) | 1991-08-10 | 1993-02-11 | Chem & Pharm Patent Hold Ltd | 3(5)-(hydroxyaryl)-pyrazole und ihre verwendung als wirkstoffe in arzneimittel |
DE4230839A1 (de) | 1991-09-18 | 1993-03-25 | Ciba Geigy Ag | Polyarylenether mit pyrazoleinheiten |
JPH06135948A (ja) | 1992-10-30 | 1994-05-17 | Taiho Yakuhin Kogyo Kk | スチレン誘導体又はその塩 |
DE4408084A1 (de) | 1994-03-10 | 1995-09-14 | Hoechst Ag | 3,5-Disubstituierte und 3,4,5-trisubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
RO119946B1 (ro) | 1995-02-13 | 2005-06-30 | G.D. Searle & Co. | Derivaţi de izoxazol, utilizaţi pentru tratamentul inflamaţiilor |
WO1997001551A1 (en) * | 1995-06-26 | 1997-01-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole compounds and pharmaceutical compositions |
US6350453B1 (en) | 1999-05-24 | 2002-02-26 | American River Nutrition, Inc. | Tocotrienols and geranylgeraniol from Bixa orellana byproducts |
CN1178931C (zh) | 1999-06-03 | 2004-12-08 | 帝国脏器制药株式会社 | 取代吡唑化合物 |
-
1999
- 1999-08-06 US US09/369,747 patent/US6291505B1/en not_active Ceased
- 1999-08-06 ES ES99940917T patent/ES2281186T3/es not_active Expired - Lifetime
- 1999-08-06 AU AU54677/99A patent/AU5467799A/en not_active Abandoned
- 1999-08-06 EP EP99940917A patent/EP1102753B1/de not_active Expired - Lifetime
- 1999-08-06 DE DE69935335T patent/DE69935335T2/de not_active Expired - Lifetime
- 1999-08-06 WO PCT/US1999/017799 patent/WO2000007996A2/en active IP Right Grant
- 1999-08-06 AT AT99940917T patent/ATE355279T1/de not_active IP Right Cessation
- 1999-08-06 JP JP2000563630A patent/JP2002522422A/ja not_active Ceased
-
2001
- 2001-09-18 US US09/954,039 patent/US6727273B2/en not_active Expired - Fee Related
-
2003
- 2003-06-12 US US10/461,914 patent/US20040077701A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69935335T2 (de) | 2007-11-22 |
WO2000007996A2 (en) | 2000-02-17 |
AU5467799A (en) | 2000-02-28 |
US6727273B2 (en) | 2004-04-27 |
US20040034081A9 (en) | 2004-02-19 |
ES2281186T3 (es) | 2007-09-16 |
US20020111374A1 (en) | 2002-08-15 |
EP1102753A2 (de) | 2001-05-30 |
ATE355279T1 (de) | 2006-03-15 |
WO2000007996A8 (en) | 2000-10-19 |
JP2002522422A (ja) | 2002-07-23 |
EP1102753B1 (de) | 2007-02-28 |
WO2000007996A3 (en) | 2000-08-31 |
US20040077701A1 (en) | 2004-04-22 |
US6291505B1 (en) | 2001-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69935335D1 (de) | Pyrazole als modulatoren des östrogenrezeptors | |
ATE315033T1 (de) | Subtituierte isoxazole derivate als estrogen rezeptor modulatore | |
YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
DE69914726D1 (de) | Zusammensetzung zur regulierung des hauterscheinungsbildes | |
BG104247A (en) | Resorcinol derivatives | |
BG106539A (en) | Bicyclic androgen and progesterone receptor modulator compounds and methods | |
EP0911321A3 (de) | Verbindungen zur Behandlung von Osteoporose | |
MX9702865A (es) | Agentes estrogenicos. | |
AP9801269A0 (en) | Prostaglandin agonists. | |
AU6045398A (en) | Androgen synthesis inhibitors | |
MX9805253A (es) | Antagonistas del receptor de vitronectina. | |
SI1054887T1 (sl) | Biciklicni pridinski in primidinski derivati kot receptorski antagonisti nevropeptida y | |
YU7797A (sh) | Kombinovana terapija za osteoporozu | |
BR9710255A (pt) | Método para o tratamento de cáncer composto de retinóide de adamantila composição farmacéutica ou cosmética de matéria método de tratamento ou de prevenção e método para controlar | |
AP1424A (en) | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens. | |
ATE264304T1 (de) | Dihydronaphthalinderivate und verfahren zur herstellung derselben | |
IL153147A0 (en) | Phospholipid derivatives of valporic acid and mixtures thereof | |
GB9712966D0 (en) | Novel chalcones | |
GB2340751B (en) | Pharmaceutical compositions | |
MY133390A (en) | Azabicyclic 5ht1 receptor ligands | |
BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
DE60103867D1 (de) | Spezielle salzform von triphenylethylenederivaten als selektive östrogenrezeptormodulatoren | |
GB9806409D0 (en) | Processes for preparing intermediates | |
EP1196428A4 (de) | Durch 11-beta-aryl-17,17-spirothiolan substituierte steroide | |
AU3894399A (en) | Benzocarbazole and indenoindole derived estrogenic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |